A. D. Beadell Investment Counsel Inc. lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,037 shares of the biopharmaceutical company’s stock after selling 3,150 shares during the quarter. Pfizer comprises about 1.3% of A. D. Beadell Investment Counsel Inc.’s investment portfolio, making the stock its 29th biggest position. A. D. Beadell Investment Counsel Inc.’s holdings in Pfizer were worth $1,525,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. HC Financial Advisors Inc. bought a new stake in Pfizer in the 4th quarter worth approximately $2,685,000. West Chester Capital Advisors Inc. bought a new stake in Pfizer in the 4th quarter worth approximately $470,000. Brown Advisory Securities LLC increased its stake in Pfizer by 2.2% in the 4th quarter. Brown Advisory Securities LLC now owns 72,085 shares of the biopharmaceutical company’s stock worth $2,605,000 after acquiring an additional 1,556 shares during the last quarter. Mutual Advisors LLC bought a new stake in Pfizer in the 4th quarter worth approximately $1,036,000. Finally, Day & Ennis LLC increased its stake in Pfizer by 9.8% in the 4th quarter. Day & Ennis LLC now owns 25,213 shares of the biopharmaceutical company’s stock worth $913,000 after acquiring an additional 2,250 shares during the last quarter. Institutional investors and hedge funds own 69.14% of the company’s stock.
In related news, VP Loretta V. Cangialosi sold 26,814 shares of the business’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $40.16, for a total transaction of $1,076,850.24. Following the completion of the transaction, the vice president now owns 102,360 shares in the company, valued at approximately $4,110,777.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Laurie J. Olson sold 10,214 shares of the business’s stock in a transaction on Monday, August 13th. The shares were sold at an average price of $41.00, for a total value of $418,774.00. Following the transaction, the insider now owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 761,230 shares of company stock valued at $29,054,690. 0.06% of the stock is owned by company insiders.
PFE opened at $42.85 on Friday. Pfizer Inc. has a 52-week low of $33.20 and a 52-week high of $42.92. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91. The firm has a market cap of $251.87 billion, a P/E ratio of 16.17, a price-to-earnings-growth ratio of 2.03 and a beta of 0.96.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.07. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The company had revenue of $13.47 billion during the quarter, compared to analysts’ expectations of $13.30 billion. During the same quarter in the previous year, the business earned $0.67 EPS. Pfizer’s revenue was up 4.4% compared to the same quarter last year. research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 4th. Investors of record on Friday, August 3rd were issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date was Thursday, August 2nd. Pfizer’s payout ratio is currently 51.32%.
A number of equities analysts have recently commented on PFE shares. Credit Suisse Group set a $39.00 target price on Pfizer and gave the stock a “hold” rating in a report on Tuesday, July 31st. Goldman Sachs Group reiterated a “neutral” rating and issued a $42.00 target price on shares of Pfizer in a report on Wednesday, August 1st. Barclays lifted their target price on Pfizer from $38.00 to $40.00 and gave the stock a “neutral” rating in a report on Thursday, August 23rd. Societe Generale reiterated a “neutral” rating and issued a $39.00 target price on shares of Pfizer in a report on Wednesday, May 30th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, July 31st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company. Pfizer presently has a consensus rating of “Hold” and an average price target of $41.89.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Read More: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.